Related Experiment Videos

[Use of betablockers in elderly patients with congestive heart failure]

Agustín Urrutia1, Josep Lupón, Salvador Altimir

  • 1Unidad de Insuficiencia Cardíaca, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain. aurrutia@ns.hugtip.scs.es

Medicina Clinica
|March 3, 2006
PubMed

Insights

Beta-blockers (BB) in elderly patients with congestive heart failure (CHF) showed good tolerance and significantly reduced one- and two-year mortality. Patients on BB had better functional status and fewer comorbidities like COPD.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Limited research exists on beta-blocker (BB) use in elderly patients with congestive heart failure (CHF).
  • Understanding BB characteristics and outcomes in this demographic is crucial for treatment optimization.

Purpose of the Study:

  • To evaluate the characteristics of elderly CHF patients treated with BB.
  • To assess the association between BB use and patient outcomes, specifically mortality.

Main Methods:

  • A cohort of patients aged 75 years and older with CHF was evaluated.
  • Clinical and functional characteristics, including mortality, were compared between patients treated with and without BB.

Main Results:

  • 47% of elderly CHF patients received BB with good tolerance; only 3 required withdrawal.
  • Patients on BB were younger, had less severe CHF (NYHA class), and fewer comorbidities (e.g., COPD).
  • One-year mortality was 5.7% in the BB group versus 27.6% in the no-BB group (p=0.01); two-year mortality was 20.68% versus 60% (p=0.002).

Conclusions:

  • Beta-blockers are well-tolerated and beneficial in elderly patients with CHF.
  • BB treatment is associated with improved functional status and significantly lower short- and medium-term mortality in this population.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...